Young-Onset Colorectal Cancer
Health & Wellness

Cleveland Clinic Research Reveals Unique Tumor-Related Bacteria Tied to Young-Onset Colorectal Cancer

6.12KViews

Cleveland Clinic Research Reveals Unique Tumor-Related Bacteria Tied to Young-Onset Colorectal Cancer

Discovery by global health system could lead to new screenings and treatments for people under 50

Young-Onset Colorectal Cancer

New research from global health system Cleveland Clinic has mapped changes in tumor-related bacteria to uncover potential new strategies to combat the rise of young-onset colorectal cancer (CRC) in people under the age of 50. 

The research reveals differences in tumor-related bacteria associated with young-onset colorectal cancer. Published in eBioMedicine (part of Lancet Discovery Science), the findings could lead to new screenings or treatments for this population.

From 1990 to 2019, global young-onset CRC cases more than doubled from around 95,000 to more than 225,000, according to the Global Cancer Association

“The unexplained rise of young-onset colorectal cancer is of great concern,” said Alok Khorana, M.D., Cleveland Clinic oncologist and primary investigator of the study. “Our team discovered that bacteria were more abundant and compositionally distinct in tumors from young-onset patients. These insights help us to better understand the disease causes and inform new prevention approaches, diagnostic markers, and therapeutic targets.” 

This retrospective study, funded by the Sondra and Stephen Hardis Family, used gene sequencing technology to compare tissue samples from 136 young-onset colorectal cancer patients with 140 average-age patients with the disease. They identified unique tumor-related bacteria in the younger cohort and found that they were more likely to have left-sided, rectal and advanced stage tumors. Key microbes associated with young-onset cancers included Akkermansia and Bacteroides

First authors of the paper were Shimoli Barot, M.D., of Cleveland Clinic Cancer Institute, and Naseer Sangwan, Ph.D., of Cleveland Clinic Lerner Research Institute. Dr. Khorana also holds the Sondra and Stephen Hardis Chair for Oncology Research.

“By detailing this microbial signature of young-onset disease, we can look toward new screening biomarkers and drugs targeting related bacteria,” said Dr. Barot

Dr. Sangwan added that “further research is needed into how lifestyle factors such as diet, medications and obesity may impact gut bacteria and contribute to young-onset colon cancers.”   

Leave a Reply